Masanobu Ueno

9PUBLICATIONS
21CO-AUTHORS
Molecular targetsRegenerative medicine (incl. stem cells)Predictive and prognostic markersInternational arbitrationAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 18, 2026
Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry.

|Mar 09, 2026
Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long-Term Multicenter Observational Study.

Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada

|Feb 05, 2026
Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.

Hidenori Sakai, Koshiro Sonomoto, Shingo Nakayamada

|Jan 16, 2026
Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry.

Masanobu Ueno, Koshiro Sonomoto, Hiroaki Tanaka

|Jan 16, 2026
Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.

Koshiro Sonomoto, Shingo Nakayamada, Hidenori Sakai

|Jan 22, 2025
Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.

Yusuke Miyazaki, Shingo Nakayamada, Hiroaki Tanaka

Pageof 2

Frequent Collaborators

9 joint publications

Yoshiya Tanaka

8 joint publications

Satoshi Kubo

7 joint publications

Yusuke Miyazaki

5 joint publications

Hidenori Sakai